
Applicability of Next-generation Sequencing Techniques in Assessing Non-alcoholic Fatty Liver Disease: A Comprehensive Review
OE01-OE05
Correspondence
Ali Mahzari,
King Fahad Road, 65779-7738, Al Aqiq, Al-Baha, Riyadh, Saudi Arabia.
E-mail: amoosa@bu.edu.sa
Non-alcoholic Fatty Liver Disease (NAFLD) is a burgeoning global health concern, with a spectrum of severity ranging from simple steatosis to Non-alcoholic Steatohepatitis (NASH). While liver biopsy remains the gold standard for diagnosis, the need for non invasive alternatives has spurred interest in Next-generation Sequencing (NGS) technologies. NGS technologies enable the simultaneous sequencing of millions of Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA) fragments, providing a high-throughput approach to analyse genetic variations, gene expression and epigenetic modifications. A comprehensive literature search was conducted to identify studies investigating the use of NGS in NAFLD. Data extraction focused on NGS techniques, study design, key findings and clinical implications. NGS has demonstrated potential in unraveling the complex genetic and molecular underpinnings of NAFLD. The identification of genetic variants, epigenetic modifications and non coding RNA alterations has advanced our understanding of disease pathogenesis. Moreover, NGS-based approaches have shown promise in differentiating NAFLD subtypes and predicting disease progression. However, challenges related to data analysis, standardisation and clinical translation persist. NGS offers a promising avenue for improving NAFLD diagnosis, prognosis and management. While significant advancements have been made, further research is needed to fully realise its clinical potential.